Abstract
CS-682 (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl)-N4-palmitoylcytosine) is a novel orally administered 2'-deoxycytidine-type antimetabolite, which has a wide spectrum of antitumor activity in human tumor xenograft models. We conducted a phase I study to define the toxicity, pharmacokinetics and antitumor activity of CS-682 in patients with advanced solid tumors. Forty patients were enrolled to receive escalating doses of CS-682. CS-682 was given orally, once daily three times a week (Monday, Wednesday and Friday), for four weeks consecutively, followed by a two-week rest period. Twenty-two men and 18 women, median age 63.5 (range 31 to 82) were treated. The most common tumor type was colorectal cancer with 15 patients. Others tumors occurring in 3 or more patients included prostate, breast and lung carcinomas. Sixty percent of the patients had received greater than 2 prior chemotherapy programs. Patients have been treated at each of the following dose levels (mg/m2/day): 1.5, 12, 20, 25, 30, 50, 67, 90, 120, 160 and 220. Non hematologic toxicities grade 3 [NCI Common Toxicity Criteria (version 2.0)] related to treatment included nausea in 2, vomiting in 1, anorexia and asthenia in 2, and dehydration in 1. Severe hemat...Continue Reading
Citations
Feb 2, 2012·Chemotherapy Research and Practice·Amy ZiembaGiuseppe Pizzorno
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop KantarjianWilliam Plunkett
Jun 29, 2012·Chinese Journal of Cancer·Xiao-Jun LiuWilliam Plunkett
May 23, 2014·Clinical Interventions in Aging·Ming Y Lim, Katarzyna Jamieson
Feb 15, 2012·Expert Opinion on Investigational Drugs·Xiaojun LiuWilliam Plunkett
Sep 29, 2011·Seminars in Oncology·Tapan M KadiaHagop Kantarjian
Feb 26, 2008·Cancer Science·Tomohiro AsaiNaoto Oku
Jul 20, 2007·British Journal of Cancer·M SerovaE Raymond
Apr 26, 2006·Journal of Physics. Condensed Matter : an Institute of Physics Journal·Jure DemsarAntoinette J Taylor
Jun 1, 2013·Nature Reviews. Drug Discovery·Lars Petter JordheimCharles Dumontet
Oct 7, 2010·British Journal of Cancer·S R GreenI N Fleming
May 3, 2014·Biological & Pharmaceutical Bulletin·Tohru ObataMotohiro Tanaka
Dec 21, 2007·Cancer Control : Journal of the Moffitt Cancer Center·Pete AndersonShaio Woo
Apr 19, 2018·Investigational New Drugs·Kamalesh SankhalaScott Kopetz